CN118085021A - 一种具有抗急性饮酒致肠道损伤活性的寡肽及其制备方法和应用 - Google Patents
一种具有抗急性饮酒致肠道损伤活性的寡肽及其制备方法和应用 Download PDFInfo
- Publication number
- CN118085021A CN118085021A CN202410060850.4A CN202410060850A CN118085021A CN 118085021 A CN118085021 A CN 118085021A CN 202410060850 A CN202410060850 A CN 202410060850A CN 118085021 A CN118085021 A CN 118085021A
- Authority
- CN
- China
- Prior art keywords
- oligopeptide
- activity
- acute
- intestinal injury
- astragalus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010038807 Oligopeptides Proteins 0.000 title claims abstract description 57
- 102000015636 Oligopeptides Human genes 0.000 title claims abstract description 57
- 230000001154 acute effect Effects 0.000 title claims abstract description 48
- 230000000694 effects Effects 0.000 title claims abstract description 37
- 208000037817 intestinal injury Diseases 0.000 title claims abstract description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 230000035622 drinking Effects 0.000 claims abstract description 39
- 235000006533 astragalus Nutrition 0.000 claims abstract description 36
- 241001061264 Astragalus Species 0.000 claims abstract description 32
- 210000004233 talus Anatomy 0.000 claims abstract description 32
- 241000699670 Mus sp. Species 0.000 claims description 24
- 230000001681 protective effect Effects 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 17
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 235000019206 astragalus extract Nutrition 0.000 claims description 12
- 238000013210 evaluation model Methods 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000003480 eluent Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 abstract description 26
- 230000000968 intestinal effect Effects 0.000 abstract description 19
- 230000002757 inflammatory effect Effects 0.000 abstract description 9
- 230000028327 secretion Effects 0.000 abstract description 7
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 239000003963 antioxidant agent Substances 0.000 abstract description 5
- 230000003078 antioxidant effect Effects 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract description 3
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 229940125898 compound 5 Drugs 0.000 description 6
- 102000003777 Interleukin-1 beta Human genes 0.000 description 5
- 108090000193 Interleukin-1 beta Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 241000045403 Astragalus propinquus Species 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 229940107666 astragalus root Drugs 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010017788 Gastric haemorrhage Diseases 0.000 description 1
- 206010022653 Intestinal haemorrhages Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 229960004232 linoleic acid Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种具有抗急性饮酒致肠道损伤活性的寡肽及其制备方法和应用,寡肽是具有Tyr‑Val‑Gly‑Trp‑Glu‑Pro氨基酸序列的黄芪寡肽;同时公开了该寡肽的制备方法以及在制备抗急性饮酒导致的肠道损伤功能的产品中的应用。该发明的寡肽能够减轻急性饮酒诱导的肠道组织细胞炎性因子的过量分泌和肠道组织抗氧化酶的活力降低,抑制急性饮酒诱导的肠道组织细胞内活性氧的含量增加,可广泛用于具有抗急性饮酒导致肠道损伤功能的食品、功能性食品、保健品及药物等领域;安全性高,制备方法简单,反应条件易行。
Description
技术领域
本发明涉及生物医药技术领域,尤其是一种具有抗急性饮酒致肠道损伤活性的寡肽及其制备方法和应用。
背景技术
饮酒对胃、肠道的损伤是与酒精或酒精代谢物的直接、间接刺激等有关。急性过量饮酒会刺激胃黏膜,导致胃黏膜的急性损伤,引发腹痛、恶心、呕吐等。大量饮酒还会导致胃炎、胃部不适、疼痛等。此外,长期大量饮酒会增加消化性溃疡风险,甚至会导致胃、肠道出血。
黄芪是一种具有益气固表、利水消肿等多种药理作用的中药材。黄芪富含多糖、黄酮类及皂苷类等活性成分;此外,黄芪含有的氨基酸、蛋白质、核黄素、维生素及亚油酸等活性成分据报道具有免疫调节等药理活性。此外,黄芪还具有抗氧化功能,能够清除体内的自由基,保护细胞免受氧化损伤。研究还报道,黄芪还具有抗疲劳、抗炎、抗肿瘤、抗衰老等多种药理作用。目前,虽有大量关于黄芪或黄芪提取物具有抗疲劳、抗衰老等的研究,但却没有将黄芪中具有保护活性的肽类物质用于抗急性饮酒导致的肠道损伤的研究及报道。
发明内容
针对现有的不足,本发明提供一种具有抗急性饮酒致肠道损伤活性的寡肽及其制备方法和应用。
本发明解决其技术问题所采用的技术方案是:一种具有抗急性饮酒致肠道损伤活性的寡肽,所述寡肽是具有Tyr-Val-Gly-Trp-Glu-Pro氨基酸序列的黄芪寡肽。
作为优选,所述黄芪寡肽是结构如下的化合物,
作为优选,所述寡肽是从黄芪中分离出来的天然寡肽。
一种具有抗急性饮酒致肠道损伤活性的寡肽的制备方法,包括如下步骤:
构建基于小鼠急性饮酒肠道损伤的评价模型;
从黄芪中提取具有不同分子量的黄芪提取物,并通过评价模型筛选出具有最佳保护活性的黄芪提取物;
将具有最佳保护活性的黄芪提取物进行初次分离获得多种具有不同活性物组分,并通过评价模型筛选出具有最佳保护活性的活性物组分;
将具有最佳保护活性的活性物组分进行二次分离获得多个化合物,并通过评价模型筛选出具有最佳保护活性的化合物,所述化合物具有Tyr-Val-Gly-Trp-Glu-Pro氨基酸序列。
作为优选,所述初次分离是通过大孔树脂色谱柱进行分离,所述二次分离是通过高效液相色谱分离。
作为优选,所述大孔树脂色谱柱分离所用的洗脱液为体积分数为15-90%的乙醇溶液。
作为优选,所述高效液相色谱分离采用梯度洗脱,其流动相是水和甲醇。
作为优选,所述黄芪提取物的提取包括如下步骤:
将黄芪在水中粉碎并超声提取获得超声提取物;
对超声提取物除糖、除脂并予以冻干获得冻干物;
将冻干物基于不同的透析膜进行透析获得不同分子量的透析液;
将透析液冻干得到黄芪提取物。
作为优选,所述透析膜的分子量为1kDa-10kDa。
一种如前任意一项所述具有抗急性饮酒致肠道损伤活性的寡肽在制备抗急性饮酒导致的肠道损伤功能的产品中的应用。
本发明的有益效果在于:该发明的寡肽能够减轻急性饮酒诱导的肠道组织细胞炎性因子(TNF-α、IL-1β)的过量分泌和肠道组织抗氧化酶(超氧化物歧化酶,SOD)的活力降低,抑制急性饮酒诱导的肠道组织细胞内活性氧(ROS)的含量增加,可广泛用于具有抗急性饮酒导致肠道损伤功能的食品、功能性食品、保健品及药物等领域;相比于普通方法获得的黄芪提取物,在相同剂量条件下能够更好的减轻抗急性饮酒导致的肠道损伤,具有更好的保护活性,安全性高,制备方法简单,反应条件易行。
附图说明
图1本发明实施例黄芪寡肽的质谱图;
图2本发明实施例黄芪寡肽抑制急性饮酒诱导的小鼠肠道损伤;
图3本发明黄芪寡肽抑制急性饮酒诱导的小鼠肠道组织炎性细胞因子过量分泌及细胞内ROS过量累积;
具体实施方式
下面将结合实施例对本发明作进一步说明,进行清楚、完整的描述,应理解,这些实施例是用于说明本发明而不限于限制本发明的范围。实施例中采用的实施条件可以根据具体厂家的条件做进一步调整,未注明的实施条件通常为常规实验中的条件。
实施例1一种具有抗急性饮酒导致肠道损伤的活性的黄芪寡肽的制备方法
①5kg鲜黄芪根洗净加水8L粉碎,粉碎物超声提取45min;对超声提取物进行除糖、除脂后进行冻干处理。冻干物基于不同的分子量(1、3、5、10kDa)透析膜透析,透析液冻干得不同分子量黄芪提取物;基于构建的小鼠急性饮酒肠道损伤评价模型评价不同分子量黄芪提取物的保护活性。
②将步骤①获得的具有最佳保护活性的组分(200g,分子量<1kDa)溶解于200mL水并用大孔树脂(ADS750)色谱(乙醇-水溶液,15%、30%、45%、70%及90%乙醇水溶液)进行洗脱,洗脱液冻干得不同活性物组分,基于构建的小鼠急性饮酒肠道损伤评价模型评价不同活性物组分的保护活性。
③将步骤②获得的具有最佳保护活性的组分(45%乙醇-水溶液洗脱组分)经高效液相色谱(HPLC)(HPLC采用C18柱(4.6×250mm,5μm,Waters,USA);流动相为:A:水,B:甲醇;梯度洗脱程序为:0-10min 35% B,11-25min 60% B;进样量为:20μL;检测波长为:260nm,310nm;流速:2.0mL/min;柱温:20℃)分离得化合物-1、化合物-2、化合物-3、化合物-4、化合物-5、化合物-6、化合物-7及化合物-8;基于构建的小鼠急性饮酒肠道损伤评价模型评价化合物-1、化合物-2、化合物-3、化合物-4、化合物-5、化合物-6、化合物-7及化合物-8的保护活性。
④将具有最佳抗急性饮酒小鼠肠道损伤保护活性的化合物-5进行结构鉴定,将其命名为黄芪寡肽,
如图1中所示,化合物-5:解析ESI-MS数据发现,m/z 750.3435是[M+H]+
离子;m/z 635.2831是y5离子;m/z 586.2988是[b5+H]+离子;m/z 394.6469是[b3-H2O+H]+离子;m/z 301.1414是[y4-H2O+H]+离子。综合以上结构解析及文献报道Marfey方法,最终鉴定化合物-5的氨基酸序列为Tyr-Val-Gly-Trp-Glu-Pro,结构式如下所示,
效果实施例:
效果实施例1黄芪寡肽提高小鼠抗急性饮酒导致的肠道损伤活性,
将4-5周Balb/c小鼠适应性饲养1周后随机分为4组,每组8只,即空白组、急性饮酒组(模型组)、市售黄芪提取物组和黄芪寡肽组。空白组:喂基础饲料;模型组:灌胃红星二锅头20mL/kg,分2次灌胃,间隔30min;市售黄芪提取物组:用蒸馏水溶解市售黄芪提取物(20mg/mL)后进行灌胃,并且是在采用与模型组相同的方法灌胃红星二锅头20mL/kg 30min后进行的;黄芪寡肽组:用蒸馏水溶解黄芪寡肽后(20mg/mL)灌胃,并且是在采用与模型组相同的方法灌胃红星二锅头20mL/kg 30min后进行的。每天观察动物行为特征,实验时间为7d。末次灌胃后禁食不禁水12h,摘眼球取血离心取血清,用于生化测定。快速取出小鼠结肠观察形态后留取标本进行相关检测。
分析本效果实施例H&E染色的结果,如图2中显示,空白组小鼠的肠结构完整,无损伤,模型组则出现了明显的腺体被破坏,杯状细胞减少以及炎症细胞浸润。相比于模型组,黄芪寡肽组能显著抑制急性饮酒导致的小鼠肠道组织损伤;相比于市售黄芪提取物,黄芪寡肽提高小鼠肠组织抗急性饮酒导致损伤的活性更强。
酒精是一种刺激性物质,长期大量饮用会对肠道黏膜造成损伤、诱发炎症反应,如肠炎、胃炎等疾病。分析本发明黄芪寡肽对急性饮酒导致的小鼠肠组织炎性细胞因子分泌的影响实验结果如图3中A、B所示。与空白组比,模型组小鼠肠组织炎性细胞因子TNF-α、IL-1β含量分别增加288.3%(p<0.01)及134.3%(p<0.01);说明,急性饮酒导致小鼠肠组织炎性因子分泌增加,加重炎症,进而导致肠组织受到严重的损伤。经本发明黄芪寡肽治疗后,急性饮酒导致的小鼠肠组织炎性因子TNF-α、IL-1β过量分泌被有效抑制。与模型组比,本发明黄芪寡肽组小鼠肠组织炎性细胞因子TNF-α、IL-1β含量分别减少22.4%(p<0.01)及19.8%(p<0.01)。进一步分析实验结果发现,相比于同等剂量的市售黄芪提取物,本发明黄芪寡肽能更好的抑制急性饮酒导致的小鼠肠组织炎性细胞因子TNF-α及IL-1β的过量分泌。
分析本效果实施例实验结果如图3中C所示,与空白组比,模型组结肠组织细胞内ROS含量增加196.4%(p<0.01);说明,急性饮酒使小鼠肠组织受到严重的氧化损伤。相比于模型组,经本发明黄芪寡肽治疗后,结肠组织细胞内ROS含量显著减少。与急性饮酒组相比,本发明黄芪寡肽组结肠组织细胞内ROS含量减少36.5%(p<0.01)。相比于同等剂量的市售黄芪提取物,本发明黄芪寡肽-I能够更好的抑制急性饮酒导致的结肠组织细胞内ROS含量升高。
分析本效果实施例本发明黄芪寡肽对急性饮酒诱导的小鼠结肠组织抗氧化酶活性的影响实验结果如图3中D可知,与空白组比,模型组SOD活性降低20.9%(p<0.01);说明,急性饮酒损伤小鼠结肠组织细胞抗氧化酶、降低其活性,进而使小鼠肠组织的抗氧化损伤活性降低。但经本发明黄芪寡肽治疗后,急性饮酒导致的小鼠结肠组织SOD抗氧化酶活性降低得到有效抑制。与模型组比,本发明黄芪寡肽组SOD活性提高14.9%(p<0.01;相比于同等剂量的市售黄芪提取物,本发明黄芪寡肽能更好的抑制急性饮酒导致的小鼠结肠组织抗氧化酶SOD活性降低,发挥更加优秀的保护活性。
该发明的黄芪寡肽属于天然寡肽,安全性高,就可以将其用于具有抗急性饮酒导致肠道损伤功能的食品、功能性食品、保健品及药物等领域。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (10)
1.一种具有抗急性饮酒致肠道损伤活性的寡肽,其特征在于:所述寡肽是具有Tyr-Val-Gly-Trp-Glu-Pro氨基酸序列的黄芪寡肽。
2.根据权利要求1所述具有抗急性饮酒致肠道损伤活性的寡肽,其特征在于:所述黄芪寡肽是结构如下的化合物,
3.根据权利要求1所述具有抗急性饮酒致肠道损伤活性的寡肽,其特征在于:所述寡肽是从黄芪中分离出来的天然寡肽。
4.一种具有抗急性饮酒致肠道损伤活性的寡肽的制备方法,其特征在于:包括如下步骤:
构建基于小鼠急性饮酒肠道损伤的评价模型;
从黄芪中提取具有不同分子量的黄芪提取物,并通过评价模型筛选出具有最佳保护活性的黄芪提取物;
将具有最佳保护活性的黄芪提取物进行初次分离获得多种具有不同活性物组分,并通过评价模型筛选出具有最佳保护活性的活性物组分;
将具有最佳保护活性的活性物组分进行二次分离获得多个化合物,并通过评价模型筛选出具有最佳保护活性的化合物,所述化合物具有Tyr-Val-Gly-Trp-Glu-Pro氨基酸序列。
5.根据权利要求4所述具有抗急性饮酒致肠道损伤活性的寡肽的制备方法,其特征在于:所述初次分离是通过大孔树脂色谱柱进行分离,所述二次分离是通过高效液相色谱分离。
6.根据权利要求5所述具有抗急性饮酒致肠道损伤活性的寡肽的制备方法,其特征在于:所述大孔树脂色谱柱分离所用的洗脱液为体积分数为15-90%的乙醇溶液。
7.根据权利要求5所述具有抗急性饮酒致肠道损伤活性的寡肽的制备方法,其特征在于:所述高效液相色谱分离采用梯度洗脱,其流动相是水和甲醇。
8.根据权利要求4所述具有抗急性饮酒致肠道损伤活性的寡肽的制备方法,其特征在于:所述黄芪提取物的提取包括如下步骤:
将黄芪在水中粉碎并超声提取获得超声提取物;
对超声提取物除糖、除脂并予以冻干获得冻干物;
将冻干物基于不同的透析膜进行透析获得不同分子量的透析液;
将透析液冻干得到黄芪提取物。
9.根据权利要求8所述具有抗急性饮酒致肠道损伤活性的寡肽的制备方法,其特征在于:所述透析膜的分子量为1kDa-10kDa。
10.一种如权利要求1至3任意一项所述具有抗急性饮酒致肠道损伤活性的寡肽在制备抗急性饮酒导致的肠道损伤功能的产品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410060850.4A CN118085021A (zh) | 2024-01-16 | 2024-01-16 | 一种具有抗急性饮酒致肠道损伤活性的寡肽及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410060850.4A CN118085021A (zh) | 2024-01-16 | 2024-01-16 | 一种具有抗急性饮酒致肠道损伤活性的寡肽及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118085021A true CN118085021A (zh) | 2024-05-28 |
Family
ID=91153865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410060850.4A Pending CN118085021A (zh) | 2024-01-16 | 2024-01-16 | 一种具有抗急性饮酒致肠道损伤活性的寡肽及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118085021A (zh) |
-
2024
- 2024-01-16 CN CN202410060850.4A patent/CN118085021A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI782283B (zh) | 一種核桃低聚肽粉的用途 | |
KR19990014205A (ko) | 플라보노이드 및 파피아 가공물을 함유한 조성물 | |
CN112870236B (zh) | 一种黄蜀葵花黄酮类有效部位及其制备方法与应用 | |
CN109608557A (zh) | 枸杞多糖提取分离和纯化方法、枸杞糖肽及制备方法 | |
CN114832022B (zh) | 一种桑黄子实体酚类活性物质的制备及其在调节肠道菌群、尿酸代谢中的应用 | |
CN113288836A (zh) | 一种祛痘复合物的制备方法与应用 | |
CN106084087A (zh) | 一种瓜蒌多糖的制备方法 | |
CN110151860A (zh) | 一种黑果枸杞提取物的制备方法及其用途 | |
CN105601707B (zh) | 一种蒲公英籽抗氧化四肽及其制备方法 | |
CN117820437B (zh) | 菊芋肽、其制备方法及其在护肾辅助糖尿病治疗抗氧化产品中的应用 | |
CN109589400B (zh) | 一种具有神经保护功效的组合物 | |
CN109364085B (zh) | 白芨寡糖及其组合物在调节糖脂代谢紊乱中的应用 | |
CN114989258B (zh) | 植物提取组合物在制备治疗便秘、减肥产品上的应用 | |
CN118085021A (zh) | 一种具有抗急性饮酒致肠道损伤活性的寡肽及其制备方法和应用 | |
CN109628523A (zh) | 枸杞多糖提取分离和纯化方法、枸杞糖肽及降血糖药物 | |
CN114668797A (zh) | 一种抗氧化降血脂护肝的植物发酵液及其制备方法和应用 | |
KR20150090463A (ko) | 피부 노화 및 염증 질환의 예방 또는 치료용 조성물, 및 건강기능식품 | |
CN111150754B (zh) | 板栗花提取物在制备食品或抗炎药物中的应用 | |
CN100554326C (zh) | 一种黄精免疫多糖、其组合物和它的用途 | |
Nan et al. | Effects of Lycium barbarum polysaccharides (LBP) on immune function of mice | |
CN105566446B (zh) | 一种蒲公英籽抗氧化肽及其制备方法与应用 | |
CN101596268B (zh) | 大蒜总皂苷在制备抗氧化应激损伤药物和食品中的应用 | |
CN118580316A (zh) | 一种山药寡肽及其抗酒精性肠道损伤功能的产品中的应用 | |
CN114480543B (zh) | 一种植物酶解肽及其抑制瘢痕、制备抑制瘢痕化妆品的用途 | |
CN116836223B (zh) | 一种青刺果活性肽组合物及新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |